The burgeoning landscape of medication for obesity and type 2 metabolic disorder is currently witnessing considerable attention surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant distinctions in their pharmacological profiles and clinical investigation results are emerging. Retat… Read More

Arriving in the arena of excess body fat treatment, retatrutide represents a unique approach. Beyond many current medications, retatrutide operates as a twin agonist, simultaneously affecting both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) binding sites. This simultaneous stimulation promotes various helpful … Read More